Transgene SA (TNG) - Net Assets
Based on the latest financial reports, Transgene SA (TNG) has net assets worth €121.73 Million EUR (≈ $142.32 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€138.83 Million ≈ $162.30 Million USD) and total liabilities (€17.09 Million ≈ $19.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Transgene SA tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €121.73 Million |
| % of Total Assets | 87.69% |
| Annual Growth Rate | 6.53% |
| 5-Year Change | 81.13% |
| 10-Year Change | 161.78% |
| Growth Volatility | 171.38 |
Transgene SA - Net Assets Trend (1997–2025)
This chart illustrates how Transgene SA's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Transgene SA to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Transgene SA (1997–2025)
The table below shows the annual net assets of Transgene SA from 1997 to 2025. For live valuation and market cap data, see Transgene SA (TNG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €121.73 Million ≈ $142.32 Million |
+700.68% |
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
-2.61% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
-58.74% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
-43.70% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
+33.75% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
-23.51% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
+79.01% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
+30.66% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
-39.60% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
+75.17% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
-63.05% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
+26.87% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
-43.14% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
-29.59% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
-22.98% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
+167.81% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
-27.23% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
-15.07% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
+484.52% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
+33.35% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
-58.77% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
-37.47% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
-25.02% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
+111.66% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
-37.29% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
-24.51% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
+255.29% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Transgene SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5123142500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €82.26 Million | 67.57% |
| Other Comprehensive Income | €-678.00K | -0.56% |
| Other Components | €116.67 Million | 95.84% |
| Total Equity | €121.73 Million | 100.00% |
Transgene SA Competitors by Market Cap
The table below lists competitors of Transgene SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vertical Aerospace Ltd
NYSE:EVTL
|
$213.54 Million |
|
Exotic Food Public Company Limited
BK:XO
|
$213.58 Million |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
$213.58 Million |
|
Azkoyen
MC:AZK
|
$213.59 Million |
|
Daewonkangup
KO:000430
|
$213.44 Million |
|
Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
NASDAQ:AXIN
|
$213.42 Million |
|
Nam Kim Steel JSC
VN:NKG
|
$213.41 Million |
|
Icelandic Salmon As
OL:ISLAX
|
$213.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Transgene SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,204,000 to 121,735,000, a change of 106,531,000 (700.7%).
- Net loss of 37,524,000 reduced equity.
- New share issuances of 105,112,000 increased equity.
- Other comprehensive income decreased equity by 678,000.
- Other factors increased equity by 39,621,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-37.52 Million | -30.82% |
| Share Issuances | €105.11 Million | +86.34% |
| Other Comprehensive Income | €-678.00K | -0.56% |
| Other Changes | €39.62 Million | +32.55% |
| Total Change | €- | 700.68% |
Book Value vs Market Value Analysis
This analysis compares Transgene SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | €5.90 | €0.75 | x |
| 1998-12-31 | €12.51 | €0.75 | x |
| 1999-12-31 | €9.42 | €0.75 | x |
| 2000-12-31 | €5.82 | €0.75 | x |
| 2001-12-31 | €8.46 | €0.75 | x |
| 2002-12-31 | €5.30 | €0.75 | x |
| 2003-12-31 | €3.31 | €0.75 | x |
| 2004-12-31 | €1.37 | €0.75 | x |
| 2006-12-31 | €1.17 | €0.75 | x |
| 2007-12-31 | €5.43 | €0.75 | x |
| 2008-12-31 | €4.11 | €0.75 | x |
| 2009-12-31 | €3.02 | €0.75 | x |
| 2010-12-31 | €6.46 | €0.75 | x |
| 2011-12-31 | €4.35 | €0.75 | x |
| 2012-12-31 | €3.06 | €0.75 | x |
| 2013-12-31 | €1.73 | €0.75 | x |
| 2014-12-31 | €1.82 | €0.75 | x |
| 2015-12-31 | €0.67 | €0.75 | x |
| 2016-12-31 | €0.80 | €0.75 | x |
| 2017-12-31 | €0.44 | €0.75 | x |
| 2018-12-31 | €0.59 | €0.75 | x |
| 2019-12-31 | €0.80 | €0.75 | x |
| 2020-12-31 | €0.60 | €0.75 | x |
| 2021-12-31 | €0.74 | €0.75 | x |
| 2022-12-31 | €0.38 | €0.75 | x |
| 2023-12-31 | €0.16 | €0.75 | x |
| 2024-12-31 | €0.13 | €0.75 | x |
| 2025-12-31 | €0.84 | €0.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Transgene SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7657.96%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-30.82%) is above the historical average (-63.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -57.33% | -176.71% | 0.22x | 1.46x | €-13.93 Million |
| 1998 | -47.62% | -300.00% | 0.14x | 1.15x | €-42.35 Million |
| 1999 | -32.85% | -421.36% | 0.06x | 1.21x | €-23.77 Million |
| 2000 | -64.62% | -475.85% | 0.10x | 1.38x | €-25.96 Million |
| 2001 | -29.81% | -1741.83% | 0.01x | 1.17x | €-29.31 Million |
| 2002 | -33.34% | -834.36% | 0.03x | 1.21x | €-23.93 Million |
| 2003 | -60.47% | -834.67% | 0.05x | 1.33x | €-24.33 Million |
| 2004 | -143.93% | -814.84% | 0.10x | 1.79x | €-21.91 Million |
| 2006 | -116.08% | -397.24% | 0.17x | 1.72x | €-23.93 Million |
| 2007 | -4.98% | -19.70% | 0.22x | 1.16x | €-16.61 Million |
| 2008 | -19.10% | -129.04% | 0.11x | 1.34x | €-27.42 Million |
| 2009 | -39.89% | -232.44% | 0.12x | 1.44x | €-34.20 Million |
| 2010 | -18.64% | -242.48% | 0.06x | 1.22x | €-52.58 Million |
| 2011 | -30.85% | -301.99% | 0.07x | 1.37x | €-57.77 Million |
| 2012 | -43.39% | -1099.87% | 0.02x | 1.61x | €-53.16 Million |
| 2013 | -75.69% | -1113.48% | 0.03x | 2.22x | €-48.52 Million |
| 2014 | -67.59% | -1950.04% | 0.02x | 1.96x | €-55.74 Million |
| 2015 | -174.69% | -3165.46% | 0.01x | 3.80x | €-49.03 Million |
| 2016 | -54.21% | -1074.47% | 0.02x | 2.64x | €-29.86 Million |
| 2017 | -114.90% | -1537.59% | 0.02x | 3.59x | €-35.08 Million |
| 2018 | 21.87% | 601.20% | 0.01x | 2.96x | €4.36 Million |
| 2019 | -28.62% | -141.43% | 0.12x | 1.76x | €-25.37 Million |
| 2020 | -36.72% | -618.92% | 0.03x | 1.70x | €-23.48 Million |
| 2021 | -29.76% | -200.18% | 0.10x | 1.52x | €-26.72 Million |
| 2022 | -86.70% | -1049.58% | 0.05x | 1.76x | €-36.59 Million |
| 2023 | -143.02% | -282.63% | 0.17x | 2.90x | €-23.89 Million |
| 2024 | -223.43% | -534.72% | 0.15x | 2.77x | €-35.49 Million |
| 2025 | -30.82% | -7657.96% | 0.00x | 1.14x | €-49.70 Million |
Industry Comparison
This section compares Transgene SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $33,954,071
- Average return on equity (ROE) among peers: -75.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Transgene SA (TNG) | €121.73 Million | -57.33% | 0.14x | $213.47 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $106.00 Million |
| Abivax SA (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.19 Billion |
| Adocia (ADOC) | $10.69 Million | -44.27% | 0.41x | $93.64 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $16.93 Million |
| Biophytis S.A. (ALBPS) | $4.52 Million | -176.01% | 0.86x | $752.91K |
| Cellectis (ALCLS) | $125.94 Million | -78.36% | 1.07x | $233.04 Million |
| Advicenne (ALDVI) | $-11.97 Million | 0.00% | 0.00x | $18.99 Million |
| Genoway (ALGEN) | $5.15 Million | 0.52% | 1.02x | $31.09 Million |
| Integragen (ALINT) | $1.48 Million | -204.25% | 1.41x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.08 Million | 0.00% | 0.00x | $1.80 Million |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more